Odette Cancer Centre

Running trials

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

  NCT06623461· Phase 2· Canadian Cancer Trials Group· Source

• Recruiting

  Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

  NCT06641791· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

  NCT06439225· Phase 3· Canadian Cancer Trials Group· Source

• Active, not recruiting

  The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person

  NCT05509751· Martine Puts· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

  NCT05845814· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  NCT05640999· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

  NCT05358639· Phase 1· Sunnybrook Health Sciences Centre· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

  NCT05217446· Phase 2· Pfizer· Source

• Recruiting

  Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

  NCT04918186· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

  NCT05116189· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

  NCT04663997· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

  NCT04586231· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

  NCT04647526· Phase 3· POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company· Source

• Recruiting

  Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.

  NCT03061435· Dr. Danielle Vicus· Source

• Active, not recruiting

  Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

  NCT04619069· Phase 1/2· Sunnybrook Health Sciences Centre· Source

• Active, not recruiting

  Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

  NCT03784755· Canadian Cancer Trials Group· Source

• Active, not recruiting

  De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

  NCT03822897· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

  NCT03624543· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT02905318· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

  NCT02960087· Canadian Cancer Trials Group· Source

• Recruiting

  Duration of Anti-PD-1 Therapy in Metastatic Melanoma

  NCT02821013· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

  NCT04838899· Sunnybrook Health Sciences Centre· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma2 recruiting
• Prostate cancer2 recruiting
• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

  NCT04895722· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

  NCT04442048· Phase 3· Canadian Cancer Trials Group· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Completed

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· Phase 3· Incyte Corporation· Source

• Completed

  Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

  NCT02788773· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

• Completed

  Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

  NCT00819208· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Brain metastases24 works · 0 trials
• Neuroendocrine tumours16 works · 0 trials
• Myelodysplastic syndromes8 works · 1 trial